You are here: Home: Audio Program Guide: OPU 1 | 2006 Audio     Go to Case Discussions Go to interview with Charles L Vogel, MD Go to interview with Gary H Lyman, MD, MPH     To listen to individual tracks, click the on the track you wish to listen to. To download tracks, right-click on the one you wish to download.         Case Discussions     Click here to download the entire interview   Track 1 Introduction Track 2 Case 1: A 61-year-old woman with a 1.9-centimeter, poorly differentiated, ER/PR-positive, HER2- negative invasive ductal carcinoma with one positive node Track 3 Risk reduction with adjuvant systemic therapies Track 4 Patient understanding of the risk of recurrence and impact of adjuvant systemic therapy Track 5 Chemotherapeutic options in the adjuvant setting Track 6 Use of growth factor support with TAC chemotherapy Track 7 Clinical guidelines for the use of prophylactic growth factors Track 8 Reducing the risk of febrile neutropenia with growth factor support Track 9 Selection of an adjuvant chemotherapeutic regimen Track 10 Prophylactic antibiotics for patients experiencing chemotherapy-induced neutropenia Track 11 Impact of chemotherapy dose reduction on efficacy in the adjuvant setting Track 12 Impact of chemotherapy-associated toxicity on completion of adjuvant chemotherapy Track 13 Case 2: A 70-year-old woman with ER/PR-negative, HER2-positive, node-positive breast cancer Track 14 Defining HER2 positivity with IHC and FISH Track 15 Selection of chemotherapy to combine with adjuvant trastuzumab in a patient with pre-existing neuropathy Track 16 Concurrent versus sequential administration of chemotherapy and trastuzumab Track 17 Tolerability of dose-dense AC followed by paclitaxel and trastuzumab Track 18 Persistence of neuropathy after taxane therapy Track 19 Potential role of gabapentinoids to prevent or ameliorate taxane-associated neuropathy Track 20 Tolerability of dose-dense chemotherapy Track 21 Case 3: A 50-year-old woman with an ulcerated, ER/PR-positive primary breast cancer and metastatic disease Track 22 Denial in patients presenting with obvious yet neglected breast cancer Track 23 Treatment considerations in patients presenting with de novo metastatic disease Track 24 Counseling patients about the curability of metastatic breast cancer Track 25 Bevacizumab as front-line therapy for metastatic breast cancer Track 26 Integrating chemotherapy and endocrine therapies in the metastatic setting Track 27 Selection of hormonal therapy in premenopausal patients who experience amenorrhea secondary to chemotherapy Track 28 Chemotherapy regimens warranting prophylactic growth factor support Track 29 Models to predict patients at high risk for febrile neutropenia Track 30 Role of local therapy in the management of metastatic disease Track 31 Case 4: A 50-year-old woman with multifocal, node-positive, infiltrating ductal carcinoma and a history of heart disease Track 32 Treatment of breast cancer for a patient with significant comorbidities Track 33 Use of epirubicin instead of doxorubicin in a patient with underlying heart disease       Charles L Vogel, MD Medical Director, Cancer Research Network Inc Plantation, Florida     Click here to download the entire interview   Track 1 Introduction Track 2 Febrile neutropenia rates with chemotherapy regimens Track 3 Bone pain associated with pegfilgrastim Track 4 Economic impact of prophylactic growth factor support Track 5 Febrile neutropenia rates associated with docetaxel Track 6 Side effects of docetaxel Track 7 Selection of a chemotherapeutic regimen for patients with node-negative, ER-positive, early breast cancer Track 8 Development and validation of the Oncotype DX™ assay Track 9 Role of the Oncotype DX assay in clinical practice       Gary H Lyman, MD, MPH Professor of Medicine and Oncology Director, Health Services and Outcomes Research James P Wilmot Cancer Center University of Rochester Medical Center Rochester, New York     Click here to download the entire interview   Track 1 Introduction Track 2 Retrospective studies of reduced chemotherapy dose intensity Track 3 Relationship between chemotherapy dose and efficacy in the adjuvant and metastatic settings Track 4 Rationale for planned and unplanned chemotherapy dose reductions Track 5 Prospective study to assess reduced chemotherapy dose intensity in community practice Track 6 Incidence of dose reductions with adjuvant chemotherapy for breast cancer Track 7 Trends in the use of adjuvant chemotherapy for breast cancer Track 8 Efficacy of pegfilgrastim versus filgrastim Track 9 Economic impact of the Oncotype DX assay Track 10 Acceptance of the Oncotype DX assay by third-party payers Track 11 Future directions, limitations and benefits of the Oncotype DX assay

Terms of Use and General Disclaimer Copyright © 2006 Research To Practice. All Rights Reserved.